HIPAA Alert: Potential Data Breach Learn More

Search
Close this search box.

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.

60 Clinical Trials
Lymphoma Phase II Accepting Patients
nct/study# NCT04728893 / MK-1026-003

A Phase 2 Study To Evaluate The Efficacy And Safety Of MK-1026 In Participants With Hematologic Malignancies

Learn More
Lymphoma NA Accepting Patients
nct/study# NA / 2021-0129

“Retrospective Review Of Outcomes And Prognostic Factors Of Patients With COVID-19 Infection And Lymphoid Malignancy”

Learn More
Lymphoma NA Accepting Patients
nct/study# NCT03888105 / R1979-ONC-1625-US

An Open-Label Study To Assess The Anti-Tumor Activity And Safety Of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Antibody, In Patients With Relapsed Or Refractory Follicular Lymphoma

Learn More
Lymphoma Phase II Accepting Patients
nct/study# NCT02742090 / TGR-1202-201

A Phase 2 Study To Assess The Safety And Efficacy Of TGR-1202 In Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant To Prior BTK (Bruton Tyrosine Kinase) Or PI3K-Delta (Phosphoinositide-3-Kinase) Inhibitor Therapy

Learn More
Lymphoma Phase II Accepting Patients
nct/study# NCT03364231 / TGR-1202-202

A Phase 2 Study To Assess The Efficacy And Safety Of TGR-1202 (Umbralisib) Monotherapy In Patients With Non-Follicular Indolent Non-Hodgkin?S Lymphoma

Learn More
Lymphoma Phase II Accepting Patients
nct/study# NCT04016805 / UTX-TGR-208

A Phase 2 Study To Assess The Efficacy And Safety Of Ublituximab And Umbralisib In Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib Or Venetoclax

Learn More

we are here for you

For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.